Cargando…

Early ART-initiation and longer ART duration reduces HIV-1 proviral DNA levels in children from the CHER trial

BACKGROUND: Reduction of the reservoir of latent HIV-infected cells might increase the possibility of long-term remission in individuals living with HIV. We investigated factors associated with HIV-1 proviral DNA levels in children receiving different antiretroviral therapy (ART) strategies in the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Payne, Helen, Chan, Man K., Watters, Sarah A., Otwombe, Kennedy, Hsiao, Nei-Yuan, Babiker, Abdel, Violari, Avy, Cotton, Mark F., Gibb, Diana M., Klein, Nigel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482761/
https://www.ncbi.nlm.nih.gov/pubmed/34587974
http://dx.doi.org/10.1186/s12981-021-00389-1
_version_ 1784576977909317632
author Payne, Helen
Chan, Man K.
Watters, Sarah A.
Otwombe, Kennedy
Hsiao, Nei-Yuan
Babiker, Abdel
Violari, Avy
Cotton, Mark F.
Gibb, Diana M.
Klein, Nigel J.
author_facet Payne, Helen
Chan, Man K.
Watters, Sarah A.
Otwombe, Kennedy
Hsiao, Nei-Yuan
Babiker, Abdel
Violari, Avy
Cotton, Mark F.
Gibb, Diana M.
Klein, Nigel J.
author_sort Payne, Helen
collection PubMed
description BACKGROUND: Reduction of the reservoir of latent HIV-infected cells might increase the possibility of long-term remission in individuals living with HIV. We investigated factors associated with HIV-1 proviral DNA levels in children receiving different antiretroviral therapy (ART) strategies in the children with HIV early antiretroviral therapy (CHER) trial. METHODS: Infants with HIV  <  12 weeks old with CD4%  ≥  25% were randomized in the CHER trial to early limited ART for 40 or 96 weeks (ART-40 W, ART-96 W), or deferred ART (ART-Def). For ART-Def infants or following ART interruption in ART-40 W/ART-96 W, ART was started/re-started for clinical progression or CD4%  <  25%. In 229 participants, HIV-1 proviral DNA was quantified by PCR from stored peripheral blood mononuclear cells from children who had received  ≥  24 weeks ART and two consecutive undetectable HIV-1 RNA 12–24 weeks apart. HIV-1 proviral DNA was compared between ART-Def and ART-96 W at week 96, and in all arms at week 248. Factors associated with HIV-1 proviral DNA levels were evaluated using linear regression. FINDINGS: Longer duration of ART was significantly associated with lower HIV-1 proviral DNA at both 96 (p  =  0.0003) and 248 weeks (p  =  0.0011). Higher total CD8 count at ART initiation was associated with lower HIV-1 proviral DNA at both 96 (p  =  0.0225) and 248 weeks (p  =  0.0398). Week 248 HIV-1 proviral DNA was significantly higher in those with positive HIV-1 serology at week 84 than those with negative serology (p  =  0.0042). INTEPRETATION: Longer ART duration is key to HIV-1 proviral DNA reduction. Further understanding is needed of the effects of “immune-attenuation” through early HIV-1 exposure. FUNDING: Wellcome Trust, National Institutes of Health, Medical Research Council.
format Online
Article
Text
id pubmed-8482761
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84827612021-10-04 Early ART-initiation and longer ART duration reduces HIV-1 proviral DNA levels in children from the CHER trial Payne, Helen Chan, Man K. Watters, Sarah A. Otwombe, Kennedy Hsiao, Nei-Yuan Babiker, Abdel Violari, Avy Cotton, Mark F. Gibb, Diana M. Klein, Nigel J. AIDS Res Ther Research BACKGROUND: Reduction of the reservoir of latent HIV-infected cells might increase the possibility of long-term remission in individuals living with HIV. We investigated factors associated with HIV-1 proviral DNA levels in children receiving different antiretroviral therapy (ART) strategies in the children with HIV early antiretroviral therapy (CHER) trial. METHODS: Infants with HIV  <  12 weeks old with CD4%  ≥  25% were randomized in the CHER trial to early limited ART for 40 or 96 weeks (ART-40 W, ART-96 W), or deferred ART (ART-Def). For ART-Def infants or following ART interruption in ART-40 W/ART-96 W, ART was started/re-started for clinical progression or CD4%  <  25%. In 229 participants, HIV-1 proviral DNA was quantified by PCR from stored peripheral blood mononuclear cells from children who had received  ≥  24 weeks ART and two consecutive undetectable HIV-1 RNA 12–24 weeks apart. HIV-1 proviral DNA was compared between ART-Def and ART-96 W at week 96, and in all arms at week 248. Factors associated with HIV-1 proviral DNA levels were evaluated using linear regression. FINDINGS: Longer duration of ART was significantly associated with lower HIV-1 proviral DNA at both 96 (p  =  0.0003) and 248 weeks (p  =  0.0011). Higher total CD8 count at ART initiation was associated with lower HIV-1 proviral DNA at both 96 (p  =  0.0225) and 248 weeks (p  =  0.0398). Week 248 HIV-1 proviral DNA was significantly higher in those with positive HIV-1 serology at week 84 than those with negative serology (p  =  0.0042). INTEPRETATION: Longer ART duration is key to HIV-1 proviral DNA reduction. Further understanding is needed of the effects of “immune-attenuation” through early HIV-1 exposure. FUNDING: Wellcome Trust, National Institutes of Health, Medical Research Council. BioMed Central 2021-09-29 /pmc/articles/PMC8482761/ /pubmed/34587974 http://dx.doi.org/10.1186/s12981-021-00389-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Payne, Helen
Chan, Man K.
Watters, Sarah A.
Otwombe, Kennedy
Hsiao, Nei-Yuan
Babiker, Abdel
Violari, Avy
Cotton, Mark F.
Gibb, Diana M.
Klein, Nigel J.
Early ART-initiation and longer ART duration reduces HIV-1 proviral DNA levels in children from the CHER trial
title Early ART-initiation and longer ART duration reduces HIV-1 proviral DNA levels in children from the CHER trial
title_full Early ART-initiation and longer ART duration reduces HIV-1 proviral DNA levels in children from the CHER trial
title_fullStr Early ART-initiation and longer ART duration reduces HIV-1 proviral DNA levels in children from the CHER trial
title_full_unstemmed Early ART-initiation and longer ART duration reduces HIV-1 proviral DNA levels in children from the CHER trial
title_short Early ART-initiation and longer ART duration reduces HIV-1 proviral DNA levels in children from the CHER trial
title_sort early art-initiation and longer art duration reduces hiv-1 proviral dna levels in children from the cher trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482761/
https://www.ncbi.nlm.nih.gov/pubmed/34587974
http://dx.doi.org/10.1186/s12981-021-00389-1
work_keys_str_mv AT paynehelen earlyartinitiationandlongerartdurationreduceshiv1proviraldnalevelsinchildrenfromthechertrial
AT chanmank earlyartinitiationandlongerartdurationreduceshiv1proviraldnalevelsinchildrenfromthechertrial
AT watterssaraha earlyartinitiationandlongerartdurationreduceshiv1proviraldnalevelsinchildrenfromthechertrial
AT otwombekennedy earlyartinitiationandlongerartdurationreduceshiv1proviraldnalevelsinchildrenfromthechertrial
AT hsiaoneiyuan earlyartinitiationandlongerartdurationreduceshiv1proviraldnalevelsinchildrenfromthechertrial
AT babikerabdel earlyartinitiationandlongerartdurationreduceshiv1proviraldnalevelsinchildrenfromthechertrial
AT violariavy earlyartinitiationandlongerartdurationreduceshiv1proviraldnalevelsinchildrenfromthechertrial
AT cottonmarkf earlyartinitiationandlongerartdurationreduceshiv1proviraldnalevelsinchildrenfromthechertrial
AT gibbdianam earlyartinitiationandlongerartdurationreduceshiv1proviraldnalevelsinchildrenfromthechertrial
AT kleinnigelj earlyartinitiationandlongerartdurationreduceshiv1proviraldnalevelsinchildrenfromthechertrial